Intravenous vitamin C for cancer

[Aurora]

For more than 20 years, the Hoffman Center has been using high-dose vitamin C drips in its cancer support protocols. The initial impetus was from Linus Pauling who, together with Ewan Cameron, pioneered the use of high-dose C in cancer in the 1960s. Now, there’s new interest in this modality for fighting cancer based on new, exciting research under way at the National Institutes of Health. Cameron and Pauling found that vitamin C helped cancer patients live about four times longer than cancer patients not given vitamin C.

They administered high-dose vitamin C in the form of sodium ascorbate given orally and intravenously to treat more than 1,000 cancer patients. Nonetheless, vitamin C for cancer suffered a setback when Dr. Charles Moertel of the Mayo Clinic, an arch foe of nutritional therapies for cancer, sought to disprove Pauling’s thesis. But he did not follow the Pauling/Cameron instructions or regimen. Moertel selected a cohort of terminal colon cancer patients who had not responded to all forms of conventional treatment, including surgery, chemo and radiation, and administered 10 grams of vitamin C to them orally.

When the patients failed to demonstrate improved survival over patients not receiving vitamin C in the study, Moertel pronounced the vitamin C/cancer hypothesis defunct. Moertel failed to note that the benefits achieved by Pauling and Cameron’s patients were obtained via both IV and oral C. He ultimately succumbed to cancer himself years later. Alternative practitioners, meanwhile, sought to resurrect IV vitamin C as a tool in the treatment of cancer, but not until recently has serious academic research resumed. Dr. Hugh Riordan of Kansas treated hundreds of cancer patients with doses of vitamin C up to 200,000 mg (200 grams) per day in infusions lasting 4-12 hours several times a week. He compiled a series of case histories documenting impressive responses but passed recently, before his work was generally acknowledged. His protegee, Dr. Jeanne Drisko, Chairman of the Department of Complementary Medicine at the Kansas University Medical Center, has undertaken a series of clinical trials to validate the benefits of IV vitamin C in cancer. An FDA approved trial is now underway. Research at the National Institutes of Health is beginning to suggest that vitamin C deserves another chance to find its niche in the arsenal of anti-cancer therapies. Studies now suggest that even high dose vitamin C given by mouth is poorly absorbed.

Blood levels “max out” at doses of 500 mg given several times during the day. But vitamin C given intravenously is another story. When delivered in a “drip,” much higher concentrations of C can be attained. At these higher concentrations, vitamin C has different characteristics than if given orally. While oral vitamin C boosts immunity and assists tissue repair, it is too weak to do much to kill or inhibit cancer cells. But at high doses delivered directly into the bloodstream, it may act to increase levels of hydrogen peroxide deep in the tissues where cancer cells lurk. Peroxide-mediated killing is one of the white blood cells’ key mechanisms for fighting infection and cancer. Research currently under way has shown that high concentrations of vitamin C can stop the growth or even kill a wide range of cancer cells. Only intravenous administration of vitamin C can deliver the high doses found to be effective against cancer.

IV vitamin C, when administered by a trained, experienced physician, is safe and well-tolerated, even at doses as high as 100,000 mg (100 grams) per day. Proper blood tests must be done to ensure that it is well-tolerated, and the patient must be monitored. Doses must be gradually adjusted upward. Not all patients are candidates for IV vitamin C. Vitamin C can be safely administered even while patients are undergoing chemo and radiation; in fact, the FDA-approved trial at Kansas University Medical Center explicitly permits the co-administration of vitamin C with conventional treatments. Intravenous vitamin C remains one of the key modalities employed by the Hoffman Center in support of recovery from cancer, and it is hoped that additional research, now under way, will further document its benefits.http://drhoffman.com/article/intrave...-for-cancer-2/

Questions and Answers About High-Dose Vitamin C

What is high-dose vitamin C?
Vitamin C (also called L-ascorbic acid or ascorbate) is a nutrient that humans must get from food or dietary supplements since it cannot be made in the body. Vitamin C is an antioxidant and helps prevent oxidative stress. It also works with enzymes to play a key role in making collagen.

When taken by intravenous (IV) infusion, vitamin C can reach much higher levels in the blood than when it is taken by mouth. Studies suggest that these higher levels of vitamin C may cause the death of cancer cells in the laboratory.

A severe deficiency (lack) of vitamin C in the diet causes scurvy, a disease with symptoms of extreme weakness, lethargy, easy bruising, and bleeding. The lack of vitamin C in patients with scurvy makes collagen thinner in texture; when vitamin C is given, collagen becomes thicker again.

What is the history and use of high-dose vitamin C as a complementary and alternative treatment for cancer?
High-dose vitamin C has been studied as a treatment for patients with cancer since the 1970s. A Scottish surgeon named Ewan Cameron worked with Nobel Prize-winning chemist Linus Pauling to study the possible benefits of vitamin C therapy in clinical trials of cancer patients in the late 1970s and early 1980's.

Surveys of healthcare practitioners at United States CAM conferences in recent years have shown that high-dose IV vitamin C is frequently given to patients as a treatment for infections, fatigue, and cancers, including breast cancer.

What is the theory behind the claim that high-dose vitamin C is useful in treating cancer?
More than fifty years ago, a study suggested that cancer was a disease of changes in connective tissue caused by a lack of vitamin C. In the 1970's, it was proposed that high-dose ascorbic acid could help build resistance to disease or infection and possibly treat cancer.

Later studies showed that the levels of vitamin C that collect in the bloodstream depend on how it is taken.

How is high-dose vitamin C administered?
Vitamin C may be given by intravenous (IV) infusion or taken by mouth, although much higher blood levels are reached when given intravenously.

Have any preclinical (laboratory or animal) studies been conducted using high-dose vitamin C?
Laboratory studies and animal studies have been done to find out if high-dose vitamin C may be useful in preventing or treating cancer.

Laboratory studies

Many laboratory studies have been done to find out how high-dose vitamin C may cause the death of cancer cells. The anticancer effect of vitamin C in different types of cancer cells involves a chemical reaction that makes hydrogen peroxide, which may kill cancer cells.

Laboratory studies have shown the following:

Treatment with high-dose vitamin C slowed the growth and spread of prostate, pancreatic, liver, colon, malignant mesothelioma, neuroblastoma, and other types of cancer cells.
Combining high-dose vitamin C with certain types of chemotherapy may be more effective than chemotherapy alone:
Ascorbic acid with arsenic trioxide may be more effective in ovarian cancer cells.
Ascorbic acid with gemcitabine may be more effective in pancreatic cancer cells.
Ascorbic acid with gemcitabine and epigallocatechin-3-gallate (EGCG) may be more effective in malignant mesothelioma cells.
Another laboratory study suggested that combining high-dose vitamin C with radiation therapy killed more glioblastoma multiforme cells than radiation therapy alone.
However, not all laboratory studies combining vitamin C with anticancer therapies have shown benefit. Combining dehydroascorbic acid, a particular form of vitamin C, with chemotherapy made it less effective in killing some kinds of cancer cells.

Animal studies

Studies of high-dose vitamin C have been done in animal models (animals given a disease either the same as or like a disease in humans).

Some of the studies showed the vitamin C helped kill more cancer cells:

High-dose vitamin C blocked tumor growth in animal models of pancreatic, liver, prostate, sarcoma, and ovarian cancers and malignant mesothelioma.
High-dose vitamin C combined with chemotherapy in a mouse model of pancreatic cancer showed that the combination treatment shrank tumors more than chemotherapy treatment alone.
Another study showed that vitamin C made a type of light therapy more effective when used to treat mice injected with breast cancer cells.
However, other animal studies have shown that vitamin C interferes with the anticancer action of certain drugs, including the following:

Mouse models of human lymphoma and multiple myeloma treated with combinations of vitamin C and chemotherapy or the drug bortezomib had more tumor growth than mice treated with bortezomib alone.
Have any clinical trials (research studies with people) of high-dose vitamin C been conducted?
Several studies of high-dose vitamin C in patients with cancer have been done in recent years, including the following:

Studies of vitamin C alone

Intravenous (IV) vitamin C was studied in patients with breast cancer who were treated with adjuvant chemotherapy and radiation therapy. The study found that patients who received IV vitamin C had better quality of life and fewer side effects than those who did not.
A study of IV vitamin C and high doses of vitamin C taken by mouth was done in patients with cancer that could not be cured. Vitamin C was shown to be a safe and effective therapy to improve quality of life in these patients, including physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss.
Vitamin C has been shown to be safe when given to healthy volunteers and cancer patients at doses up to 1.5 g/kg, while screening out patients with certain risk factors who should avoid vitamin C. Studies have also shown that Vitamin C levels in the blood are higher when taken by IV than when taken by mouth, and last for more than 4 hours.
Studies of vitamin C combined with other drugs

Studies of vitamin C combined with other drugs have shown mixed results:

In a small study of 14 patients with advanced pancreatic cancer, IV vitamin C was given along with chemotherapy and treatment with a targeted therapy. Patients had very few bad side effects from the vitamin C treatment. The nine patients who completed the treatment had stable disease as shown by imaging studies.
In another small study of 9 patients with advanced pancreatic cancer, patients were given chemotherapy in treatment cycles of once per week for 3 weeks along with IV vitamin C twice per week for 4 weeks. These patients had disease that did not progress for a period of months. The combined treatment was well tolerated and no serious side effects were reported.
Patients with acute myeloid leukemia, refractory metastatic colorectal cancer, or metastatic melanoma treated with vitamin C combined with other drugs had serious side effects and the disease got worse.
Have any side effects or risks been reported from high-dose vitamin C?
Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials. However, high-dose vitamin C may be harmful in patients with certain risk factors.

In patients with a history of kidney disorders, kidney failure has been reported after ascorbic acid treatment. Patients with a tendency to develop kidney stones should not be treated with high-dose vitamin C.
Case reports have shown that patients with an inherited disorder called G-6-PD deficiency should not be given high doses of vitamin C, due to the risk of hemolysis (a condition in which red blood cells are destroyed).
Since vitamin C may make iron more easily absorbed and used by the body, high doses of the vitamin are not recommended for patients with hemochromatosis (a condition in which the body takes up and stores more iron than it needs).
Have any drug interactions been reported from combining high-dose vitamin C with anticancer drugs?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs. High-dose vitamin C, when combined with some anticancer drugs, may cause them to be less effective. So far, these effects have been seen only in some laboratory and animal studies. No clinical trials have been done to further research these drug interactions in humans.

Combining vitamin C with an anticancer drug called bortezomib has been studied in cell cultures and in animal models. Bortezomib is a targeted therapy that blocks several molecular pathways in a cell, causing cancer cells to die. Several studies showed that vitamin C made bortezomib less effective, including in multiple myeloma cells. A study in mice transplanted with human prostate cancer cells, however, did not show that giving the mice different doses of vitamin C by mouth made bortezomib therapy less effective.
An oxidized form of vitamin C called dehydroascorbic acid has been studied in cell cultures and in animals with tumors. Several studies have found that high doses of dehydroascorbic acid can interfere with the anticancer effects of several chemotherapy drugs. Dehydroascorbic acid is found in only small amounts in dietary supplements and in fresh foods.
See Question 5 and Question 6 for more information on combining vitamin C with anticancer drugs.

Is high-dose vitamin C approved by the U.S. Food and Drug Administration for use as a cancer treatment in the United States?
The U.S. Food and Drug Administration (FDA) has not approved the use of high-dose vitamin C as a treatment for cancer or any other medical condition.

Because dietary supplements are regulated as foods, not as drugs, FDA approval is not required unless specific claims about disease prevention or treatment are made.http://www.cancer.gov/cancertopics/p.../patient/page2

[Prisoner Of Ice]

Mayo clinic is serious scumbags. They would make all health supplements prescription only if they could.